Clinical trial
Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema…
NCT00167518 · University of Sydney, Other · Completed
Key facts
| NCT number | NCT00167518 |
|---|---|
| Title | Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO) |
| Official title | Phase II/III Intravitreal Triamcinolone for Treatment of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment |
| Lead sponsor | University of Sydney, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Macular Oedema |
| Intervention type | Drug |
| Interventions | Triamcinolone acetate |
| Enrollment | 70 |
| Start date | Mar 1, 2002 |
| Completion | Apr 1, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | Sep 14, 2005 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: